---
title: "Aurinia publishes corporate presentation outlining LUPKYNIS growth strategy, aritinercept development plans"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295107625.md"
description: "Aurinia Pharmaceuticals released a corporate presentation detailing the growth strategy for its lupus nephritis drug LUPKYNIS and development plans for aritinercept. For the six months ended June 30, 2026, Aurinia reported total revenue of USD 160.9 million and net income of USD 71.8 million. The company provided 2026 guidance projecting total revenue between USD 315 million and USD 325 million."
datetime: "2026-08-06T12:28:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295107625.md)
  - [en](https://longbridge.com/en/news/295107625.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295107625.md)
generator: "portal-rs"
---

# Aurinia publishes corporate presentation outlining LUPKYNIS growth strategy, aritinercept development plans

-   Aurinia highlighted continued commercial growth for lupus nephritis drug LUPKYNIS. \* Six months ended June 30, 2026: total revenue USD 160.9 million; net income USD 71.8 million; operating cash flow USD 85.1 million. \* 2026 guidance: total revenue USD 315 million to USD 325 million; net product sales USD 305 million to USD 315 million. \* Pipeline focus included advancing aritinercept development in autoimmune disease. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [AUPH.US](https://longbridge.com/en/quote/AUPH.US.md)

## Related News & Research

- [Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug](https://longbridge.com/en/news/296500759.md)
- [Diamond Hill Capital Management LLC Investment Advisor Purchases New Position in Aurinia Pharmaceuticals Inc $AUPH](https://longbridge.com/en/news/296195979.md)
- [JAGX: Q2 2026 revenue fell 60% year-over-year as focus shifted to rare disease drug development](https://longbridge.com/en/news/296396312.md)
- [Aurinia settles Teva patent suit, sets generic voclosporin launch no earlier than Dec. 7, 2036](https://longbridge.com/en/news/296394736.md)
- [Ascentage Pharma posts interim results presentation on 1H 2026 business update](https://longbridge.com/en/news/296418315.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**